within Pharmacolibrary.Drugs.ATC.M;

model M09AX14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.17,
    Cl             = 16.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007,
    Tlag           = 13.2
  );

  annotation(Documentation(
    info ="<html><body><p>Givinostat is an orally active, selective histone deacetylase (HDAC) inhibitor investigated primarily for the treatment of rare genetic disorders such as Duchenne muscular dystrophy (DMD) and polycythemia vera. It is not widely approved but has orphan drug status and is under clinical development.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported from adult and pediatric patients in clinical trials receiving oral givinostat for Duchenne muscular dystrophy and hematologic malignancies.</p><h4>References</h4><ol><li><p>Fiorentini, F, et al., &amp; Bettica, P (2023). Population pharmacokinetic-pharmacodynamic analysis of givinostat. <i>Expert opinion on drug metabolism &amp; toxicology</i> 19(4) 229–238. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2023.2219839&quot;>10.1080/17425255.2023.2219839</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37306105/&quot;>https://pubmed.ncbi.nlm.nih.gov/37306105</a></p></li><li><p>Furlan, A, et al., &amp; Dinarello, CA (2011). Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). <i>Molecular medicine (Cambridge, Mass.)</i> 17(5-6) 353–362. DOI:<a href=&quot;https://doi.org/10.2119/molmed.2011.00020&quot;>10.2119/molmed.2011.00020</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21365126/&quot;>https://pubmed.ncbi.nlm.nih.gov/21365126</a></p></li><li><p>Zhan, R, et al., &amp; Chen, X (2025). UPLC-MS/MS Method for Givinostat in Rat Plasma: Development, Validation, in vivo Pharmacokinetics Study and in vitro Metabolic Stability Research. <i>Drug design, development and therapy</i> 19 219–228. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S497308&quot;>10.2147/DDDT.S497308</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39830785/&quot;>https://pubmed.ncbi.nlm.nih.gov/39830785</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M09AX14;
